Burmese pythons display a marked increase in heart mass after a large meal. We investigated the molecular mechanisms of this physiological heart growth with the goal of applying this knowledge to the mammalian heart. We found that heart growth in pythons is characterized by myocyte hypertrophy in the absence of cell proliferation and by activation of physiological signal transduction pathways. Despite high levels of circulating lipids, the postprandial python heart does not accumulate triglycerides or fatty acids. Instead, there is robust activation of pathways of fatty acid transport and oxidation combined with increased expression and activity of superoxide dismutase, a cardioprotective enzyme. We also identified a combination of fatty acids in python plasma that promotes physiological heart growth when injected into either pythons or mice.
Burmese pythons display a marked increase in heart mass after a large meal. We investigated the molecular mechanisms of this physiological heart growth with the goal of applying this knowledge to the mammalian heart. We found that heart growth in pythons is characterized by myocyte hypertrophy in the absence of cell proliferation and by activation of physiological signal transduction pathways. Despite high levels of circulating lipids, the postprandial python heart does not accumulate triglycerides or fatty acids. Instead, there is robust activation of pathways of fatty acid transport and oxidation combined with increased expression and activity of superoxide dismutase, a cardioprotective enzyme. We also identified a combination of fatty acids in python plasma that promotes physiological heart growth when injected into either pythons or mice.
T he mammalian heart is a highly adaptable organ that demonstrates remarkable cellular remodeling in the face of both pathological and physiological stimuli. Pathological hypertrophic signaling cascades, including those mediated by the a1-adrenergic and endothelin receptors, can be activated by insults such as myocardial infarction, chronic hypertension, or genetic mutations affecting sarcomeric or calciumhandling proteins. This ultimately results in increased cell size, enhanced sarcomere assembly, and activation of a "fetal" gene program, with increased expression of b-myosin heavy chain (b-MHC), a-skeletal actin, atrial natriuretic peptide, and brain natriuretic peptide, accompanied by reduced expression of a-MHC and SERCA2 (sarcoplasmic reticulum Ca 2+ adenosine triphosphatase-2) (1-3).
Pathological insults also typically result in a switch in metabolic substrate utilization from lipid oxidation to glucose utilization and increased apoptosis and fibrosis (1, 3) . Conversely, physiological cardiac hypertrophy resulting from postnatal growth, pregnancy, or exercise is primarily mediated by insulin-like growth factor-1 (IGF-1) signaling and activation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling in the absence of fetal gene program activation (4, 5) . Unlike pathological cardiac hypertrophy, this adaptive hypertrophy does not appear to be detrimental to cardiac function. In fact, exercise-induced physiological cardiac growth protects the heart against pathological stimuli such as pressure overload (6) .
The infrequently feeding Burmese python (Python molurus) has been described as a model of extreme metabolic regulation in which many organs, including the heart, increase in mass after a large meal (7, 8) . Whereas most mammalian models of physiological hypertrophy typically demonstrate modest hypertrophy (~10 to 20%) after weeks of stimulation, the python heart grows in mass by 40% within 48 to 72 hours after consumption of a large meal (7) (8) (9) . This remarkable cardiac hypertrophy is accompanied by increased cardiac output and appears to be an adaptive response to support the large (factor of~44) increase in postprandial metabolic rate, accompanied by increased systemic nutrient transport and widespread organ growth, required to accommodate such a large meal (7) (8) (9) (10) (11) (12) . The cardiac hypertrophy observed in P. molurus has Python small in-been described, but the underlying molecular and cellular mechanisms have yet to be determined (7, 8, 13) . Given that pathological cardiac hypertrophy is a leading predictor of mortality, we sought to understand the cellular and molecular components of this rapid cardiac enlargement and potentially identify previously unknown mechanisms regulating physiological cardiac growth. Similar to previous reports, we observed a progressive increase in heart size over the postfeeding time period (Fig. 1A and fig. S1A ), with a maximum increase seen at 3 days post-feeding (dpf ) ( fig. S1A) (14) . As in mammals, cardiac growth in the python appeared to be hypertrophic rather than hyperplastic, as there was no sign of 5-bromo-2´-deoxyuridine (BrdU) incorporation in the postprandial heart (Fig. 1B) . Although the cellular architecture of the python ventricle did not allow for reliable quantification of myocyte size ( fig. S1B ), we observed a significant reduction in the number of nuclei per field in the 3-dpf ventricle, providing indirect evidence of cellular hypertrophy in the absence of cell division (Fig. 1C) .
The fasted python myocardium was significantly more fibrotic than a normal mammalian heart (~18% versus~1 to 2%) (15) , and the degree of fibrosis remained relatively unchanged throughout digestion of the meal ( fig. S1C) . The postprandial python heart demonstrated an atypical pattern of gene expression, with increased expression of both SERCA2 and askeletal actin mRNA, as well as a progressive increase in both MYH7 (encoding b-MHC) and the less characterized striated muscle myosin heavy-chain gene MYH15, which also encodes the predominant MHC isoform expressed in the chicken heart ( fig. S2) (16) . Western blot analyses revealed increased phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), Akt, glycogen synthase kinase-3b (GSK3b), and mammalian target of rapamycin (mTOR) during the postprandial period ( Fig. 1D  and fig. S3 ), indicating robust activation of protein synthetic pathways in the postprandial python heart. Consistent with published observations (7), we observed a factor of 52 increase in plasma triglycerides (TAG) and a factor of 3 increase in non-esterified fatty acids (NEFAs) at 1 dpf ( Fig.  2A) . In most mammals, comparable plasma triglyceride concentrations would result in pathogenic lipid deposition in nonadipose tissues such as the heart (17). In the python heart, however, thin-layer chromatography (TLC) and Oil Red O analysis did not reveal any evidence of lipid accumulation during the postprandial period ( Fig. 2B and fig. S4A ). We also found no change in cardiac transcript levels of very-low-density lipoprotein receptor, which suggests that utilization of triglyceride-rich lipoprotein particles is not altered after feeding ( fig. S4B ). Despite this lack of cardiac lipid accumulation, expression of the fatty acid transporter CD36 was increased by a factor of 13 at 1 dpf (Fig. 2C) . mRNA levels of both muscle-type fatty acid binding protein (mFABP) and carnitine palmitoyltransferase 1B (CPT1B) were significantly increased after feeding (Fig. 2C ), as were mitochondrial cytochrome oxidase (COX2) expression and nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR) staining (Fig. 2B) . We also observed increased expression of several oxidative genes at 1 and 3 dpf, including medium-chain acyl-CoA dehydrogenase (MCAD), enoyl-CoA hydratase (ECHD), and acetyl-CoA acyltransferase 2 (ACAA2) (Fig. 2C) . Together, these data suggest that there is increased oxidative capacity in the postprandial python heart. These apparent alterations in mitochondrial electron transport chain flux were coupled with a significant increase in both expression and activity of the cardioprotective free radicalscavenging enzyme superoxide dismutase-2 (SOD2) (Fig. 2D) (18) . We found no evidence of increased reactive oxygen species in the postprandial heart ( fig. S5) .
To investigate the possibility that the systemic changes observed in the python were due to circulating factors, we tested the effect of python plasma on neonatal rat ventricular myocytes (NRVMs) in culture. Treatment of NRVMs with fed plasma significantly increased cell size and a-actinin organization (Fig. 3A and fig. S6 ). The degree of NRVM growth induced by the specific postprandial plasma time points mimicked the time profile of in vivo python heart growth ( Fig. 3A and fig. S1A ), which suggests that the plasma concentrations of the hypertrophic factors varied throughout digestion. Whereas cells treated with the a-adrenergic agonist phenylephrine clearly showed robust activation of pathological patterns of gene expression, we found no such gene activation in cells treated with python plasma (Fig. 3B) . We also determined that treatment of NRVMs with fed python plasma resulted in increased IGF-1 mRNA expression and enhanced the phosphorylation of mTOR and p70S6K ( fig. S7 ). Intriguingly, fasted or fed python plasma significantly repressed activity of the transcription factor NFAT, a canonical indicator of pathological hypertrophic signaling, in NRVMs (Fig. 3C) . Finally, treatment of NRVMs with fed python plasma significantly increased the expression of genes encoding key lipid-handling (mFABP) and metabolism proteins (CPT1B, MCAD, and ACAA2) in a manner similar to that observed in the fed python heart (fig. S8 ). Given the substantial alterations seen in postprandial plasma lipid content and the evidence that heat treatment and protease K digestion were ineffective in eliminating the prohypertrophic effects of the fed python plasma ( fig. S9) , we focused our attention on lipid species as candidate prohypertrophic factors. We found that pretreatment of NRVMs with sulfosuccinimidyl oleate (SSO) (19) , an irreversible inhibitor of CD36, completely blocked the prohypertrophic effect of fed plasma ( fig. S10 ). We then analyzed fasted and post-fed python plasma by gas chromatography (GC) and observed a highly complex composition of circulating fatty acids with distinct patterns of abundance over the course of digestion ( fig. S11 ). On the basis of these data, we identified five candidate fatty acids for further analysis ( fig. S12 ) and determined that supplementing fasted python plasma with the 1-dpf molar ratio of C14:0 (myristic acid), C16:0 (palmitic acid), and C16:1 ( palmitoleic acid) effectively recapitulated the increase in NRVM cell diameter seen with 1-dpf plasma (Fig. 3D) . Similar to the effects seen with fed python plasma, treatment of NRVMs with this fatty acid mixture resulted in robust up-regulation of CD36, mFABP, CPT1, MCAD, and ACAA2 mRNA expression ( fig. S8 ). Despite the established, pro-apoptotic properties of palmitic acid in cardiomyocytes (20) (21) (22) , we did not find any evidence of apoptosis in NRVMs cultured in the presence of python plasma or the fatty acid combination (fig. S13 ). These data suggest that palmitoleic acid may protect cardiomyocytes from apoptosis in the presence of palmitic acid. Although the mechanism for this protection is unknown, it is possible that the presence of palmitoleic acid combined with increased oxidative capacity and free radicalscavenging capacity may act to reduce the generation of toxic, pro-apoptotic intermediates such as ceramide and reactive oxygen species, and to enhance the activity of cardioprotective pathways such as triglyceride biosynthesis and b-oxidation (21) (22) (23) .
To investigate the ability of these fatty acids to trigger cardiac growth in vivo, we infused fasted pythons with the same mixture of myristic, palmitic, and palmitoleic acid and determined that this lipid infusion was as effective at stimulating cardiac growth as either feeding itself or infusion of plasma from a fed snake (Fig. 4A) . We then administered the fatty acid mixture to mice over a 7-day period and observed a significant increase in left ventricular mass (Fig. 4B) , increased cardiomyocyte cross-sectional area (Fig. 4B) , no activation of the pathological fetal gene program (Fig. 4C) , and no evidence of alterations in cardiac fibrosis or lipid deposition ( fig. S14) . The growth-inducing effects of the fatty acids appeared to be cardiac-specific, as there were no observed alterations in either liver or skeletal muscle mass ( fig. S15A) . As a control, we also administered a mixture of oleic (C18:1), , and arachidonic (C20:4) acid in the molar ratio observed in the 1-dpf python and saw no evidence of cardiac hypertrophy (fig. S15B) ; this finding suggests that the prohypertrophic effects are specific to the mixture of myristic, palmitic, and palmitoleic acid. Palmitoleic acid was recently characterized as a lipokine that can modulate systemic insulin sensitivity (24) . Additionally, fatty acid ethanolamides (FAEs) have been described as potent regulators of energy intake, and levels of the palmitoleic acid ethanolamide palmitoleoylethanolamide (and other FAEs) are markedly increased in the fed python gastrointestinal tract (25) . Together, these data and our data suggest multiple roles for palmitoleic acid and its metabolites in the regulation of insulin sensitivity, organ size, cardiac metabolism, and energy balance (24) (25) (26) .
Our results indicate that postprandial cardiac growth in the python is characterized by cellular hypertrophy in the absence of hyperplasia and activation of physiological signaling pathways. Despite elevations in circulating triglycerides and increased fatty acid transport, the python heart appears to be protected from lipid deposition through increased oxidative capacity and induction of free radical-scavenging activity. Finally, we have shown that a combination of fatty acids, identified in postprandial python plasma, promotes physiological hypertrophy in mammalian cardiomyocytes. Given that activation of adaptive, physiological hypertrophic processes can provide functional benefit in the context of a cardiac disease state, our data indicate that fatty acid supplementation may provide a new mechanism for modulating cardiac gene expression and function in mammals, and that such interventions could augment cardiac performance in the context of human disease.
